Lupin moves up on getting USFDA’s tentative nod for Empagliflozin, Linagliptin Tablets

24 Jul 2020 Evaluate

Lupin is currently trading at Rs. 870.65, up by 7.80 points or 0.90% from its previous closing of Rs. 862.85 on the BSE.

The scrip opened at Rs. 865.00 and has touched a high and low of Rs. 873.00 and Rs. 865.00 respectively. So far 13501 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 955.85 on 15-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 919.00 and Rs. 846.30 respectively. The current market cap of the company is Rs. 39094.96 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.

Lupin has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (RLD: Glyxambi) had an annual sales of approximately $242 million in the U.S. (IQVIA MAT Mar 2020).

Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×